NCT05636319

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 14,168 (actual)
• Sponsor: Suzhou Abogen Biosciences Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination

Conditions

• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	ABO1020	Vaccine
BIOLOGICAL	Placebo	Placebo

Timeline

• Start date: 2022-11-23
• Primary completion: 2023-04-30
• Completion: 2024-07-31
• First posted: 2022-12-05
• Last updated: 2024-08-07

Locations

25 sites across 4 countries: Indonesia, Pakistan, Philippines, United Arab Emirates